Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(7 months ago) | |
US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(3 years from now) | |
US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 29 days ago) | |
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 29 days ago) | |
US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(7 months ago) | |
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(a month ago) | |
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) |
Isentress is owned by Msd Sub Merck.
Isentress contains Raltegravir Potassium.
Isentress has a total of 11 drug patents out of which 7 drug patents have expired.
Expired drug patents of Isentress are:
Isentress was authorised for market use on 21 December, 2011.
Isentress is available in tablet, chewable;oral, powder;oral, tablet;oral dosage forms.
Isentress can be used as treatment of hiv infection.
The generics of Isentress are possible to be released after 02 June, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Nov 22, 2020 |
Pediatric Exclusivity(PED) | May 22, 2021 |
New Dosage Form(NDF) | Dec 21, 2014 |
M(M-114) | Mar 28, 2015 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET, CHEWABLE;ORAL; POWDER;ORAL; TABLET;ORAL